Overview

Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

Up to 30-40% of the patients may develop bladder recurrance after radical nephroureterectomy for primary upper tract urothelial carcinoma. Bladder tumor needs transurethral resection, which is associated with costs of treatment and potential poor prognosis. Although several randomized controlled trial have shown that prophylactic intravesical chemotherapy could prevent bladder tumor recurrence, the optimal schedule and duration of treatment are unkown. The investigators want to determine the efficiacy of single instillation versus long-term intravesical instillation of pirarubicin for bladder recurrence after radical nephrouretectomy for primary upper tract urothelial carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

RenJi Hospital

Collaborators:

Shanghai Pudong Hospital
Shanghai Pudong New Area Gongli Hospital

Treatments:

Doxorubicin
Pirarubicin